Qualys (QLYS) News Roundup for Nov. 7–8, 2025: Analyst Upgrade, EPS Estimate Lift, and Stock Holds Near $150 After Q3 Beat

Qualys (QLYS) News Roundup for Nov. 7–8, 2025: Analyst Upgrade, EPS Estimate Lift, and Stock Holds Near $150 After Q3 Beat

Dateline: November 8, 2025 — Cybersecurity vendor Qualys, Inc. (NASDAQ: QLYS) stayed in the headlines heading into the weekend, with fresh analyst reactions following Tuesday’s earnings beat, a state pension fund disclosing a larger stake, and continued chatter around its agentic‑AI roadmap. Below is a concise, Google News–ready digest of everything new about Qualys published November 7–8, 2025.


Key Points at a Glance

  • Upgrade today: Wall Street Zen shifted QLYS to “Buy.” (MarketBeat summary). [1]
  • Forecast lift: William Blair raised its Q1‑2026 EPS estimate to $1.26 (from $1.12), citing stronger near‑term profitability. (MarketBeat summary). [2]
  • Institutional activity (Nov. 7):STRS Ohio disclosed it boosted its Qualys holdings last quarter. (MarketBeat filing brief). [3]
  • Price context (today):QLYS last traded around $149.73; 52‑week range $112.61–$159.73, per Reuters. [4]
  • Why the attention: On Nov. 4, Qualys beat Q3 expectations and raised full‑year guidance (revenue to $665.8–$667.8M; non‑GAAP EPS to $6.93–$7.00). [5]

Today — Saturday, Nov. 8, 2025

Analyst upgrade to “Buy.” MarketBeat reports that Wall Street Zen upgraded Qualys shares to Buy today, pointing to the company’s updated FY25 outlook following this week’s results. While this is one datapoint among a mixed street view, upgrades often keep post‑earnings momentum in focus. [6]

EPS estimate raised. In a separate note highlighted by MarketBeat, William Blair lifted its Q1‑2026 EPS estimate to $1.26 (from $1.12). That upward revision reflects improving operating leverage after Qualys’ Q3 delivery and updated guide. [7]

Price snapshot. As of today, Reuters shows QLYS around $149.73, with a 52‑week band of $112.61–$159.73—placing shares closer to the upper end of their one‑year range post‑earnings. [8]

Momentum chatter. A Saturday technical read from StockTradersDaily flagged “near‑term strong sentiment” but noted a neutral medium‑ to long‑term setup—another sign traders are still digesting this week’s results. [9]

Media mention (AI angle). Yahoo Finance featured a weekend story on “under‑the‑radar” AI names that included Qualys, citing its work on agentic AI in risk operations—an area the company formally unveiled over the summer. [10]


Friday, Nov. 7, 2025

State fund adds to QLYS. MarketBeat’s filing roundup says STRS Ohio increased its Qualys stake last quarter. The position change lands one day after Qualys’ report and may be read as a confidence marker from a large institution. [11]

Earnings coverage continues. Yahoo Finance recapped the beat on both revenue (~$170M) and statutory EPS ($1.39), echoing the core numbers investors have been trading on since Tuesday’s release. [12]

Investor explainer piece. Simply Wall St also published a Friday analysis noting shares were sharply higher post‑print and reiterating the updated outlook, keeping the story in front of retail investors into the weekend. [13]

From the Qualys blog (Nov. 7). The company posted a fresh technical write‑up on a large automotive data‑leak case study, tying it to cloud‑misconfiguration lessons for AWS users—useful context for customers evaluating the platform’s risk‑reduction chops. [14]


Context: What Qualys Reported on Nov. 4 (and Why It Matters)

  • Q3 FY25 results:Revenue $169.9M (+10% YoY); non‑GAAP EPS $1.86; GAAP EPS $1.39; Adjusted EBITDA $82.6M with stronger gross and operating margins. [15]
  • Q4 FY25 guide: Revenue $172–$174M; non‑GAAP EPS $1.73–$1.80. [16]
  • Full‑year FY25 guide raised: Revenue to $665.8–$667.8M (about 10% YoY growth) and non‑GAAP EPS to $6.93–$7.00. [17]

These numbers underpinned this week’s rally and set the stage for analysts to revisit models into year‑end.


Strategy & Product Backdrop to the AI Mentions

The weekend AI chatter references Qualys’ summer launch of an agentic AI–powered Risk Operations Center, designed to automate risk workflows with a marketplace of cyber risk agents embedded in the Enterprise TruRisk Management platform. That product direction continues to shape how investors categorize Qualys among AI‑levered security names. [18]


What’s Next on the Calendar

Qualys management is slated to appear at the UBS Global Technology & AI Conference in Scottsdale on Dec. 2, 2025 (2:15 p.m. MT), with a webcast via the company’s investor relations site—another venue where commentary on billings, platform adoption and AI may surface. [19]


Bottom Line

For Nov. 7–8, 2025, the new, incremental developments are an upgrade to Buy, a higher near‑term EPS estimate, fresh institutional‑holder interest, and continued media focus on Qualys’ agentic‑AI positioning. All of it layers on top of Tuesday’s clean beat and raised FY25 guide, helping keep QLYS trading near $150 into the weekend. [20]


Disclosure: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities.

insiders are SELLING! QUALYS Stock’s Biggest Dips – Time to Worry or Buy? 🔍📉

References

1. www.marketbeat.com, 2. www.marketbeat.com, 3. www.marketbeat.com, 4. www.reuters.com, 5. www.prnewswire.com, 6. www.marketbeat.com, 7. www.marketbeat.com, 8. www.reuters.com, 9. news.stocktradersdaily.com, 10. finance.yahoo.com, 11. www.marketbeat.com, 12. finance.yahoo.com, 13. simplywall.st, 14. blog.qualys.com, 15. www.prnewswire.com, 16. www.prnewswire.com, 17. www.prnewswire.com, 18. www.prnewswire.com, 19. www.qualys.com, 20. www.marketbeat.com

Stock Market Today

  • Is There a Future for Beyond Meat? Growth, Dilution, and Turnaround Prospects
    November 8, 2025, 4:18 PM EST. Beyond Meat has transitioned from a beloved growth story to a meme stock casualty. After a peak in 2021, sales have declined as competition from Impossible Foods and a peaking plant-based trend weighed on profitability. The company has funded losses by selling stock, creating a painful dilution spiral that crushed share value-down more than 99% from its all-time high. A debt-restructuring plan briefly sparked a short squeeze, but the rebound faded as quarterly results disappointed. While the debt deal staves off bankruptcy for now, the path to a sustainable turnaround hinges on returning to profitability and restoring consistent demand. Investors are advised to weigh the risks of further dilution and uncertain market demand before taking new positions.
  • Bitwise Solana ETF Draws Strong Inflows as Bitcoin, Ethereum Funds Shed Assets
    November 8, 2025, 4:16 PM EST. Bitwise's Solana Staking ETF (BSOL) debuted on Oct. 28 and has generated over $545 million in net inflows, including about $223 million in seed investments, per Farside Investments. In its first full week, BSOL posted more than $126 million in inflows, underscoring strong demand for Solana exposure even as SOL prices slide. By contrast, spot Bitcoin ETFs have shed more than $2.1 billion and nine Ethereum funds about $579 million. Solana's price has fallen roughly 29% in the past month as macro uncertainty pressures crypto assets. Analysts note BSOL's 100% staking design and NYSE listing as positives, with inflows reported on eight straight days and the share price rising about 5% on Friday.
  • Solana sinks as Bitcoin correlation drives capitulation; near-term outlook
    November 8, 2025, 4:14 PM EST. Solana's price extends its downtrend as the altcoin remains tightly correlated with Bitcoin. The Solana-Bitcoin correlation sits around 0.97, so BTC weakness drives SOL's moves. With Bitcoin hovering near the $100,000 level, SOL faces continued downside pressure and limited independent upside. Macro momentum shows Solana's Net Unrealized Profit and Loss (NUPL) in the capitulation zone, historically signaling investors reluctant to sell at a loss. Capitulation can precede a rebound, but the near-term path stays bearish: a drop toward $150, potentially $146. A bounce could push SOL toward $163 and maybe $175 if buying interest returns. Conversely, a break below $146 could target $140, deepening losses and undermining a quick recovery thesis.
  • CareCloud (CCLD) valuation reassessed after 17% weekly jump
    November 8, 2025, 4:12 PM EST. CareCloud (CCLD) has resumed momentum, up 17% over the past week, with three-month gains adding to a broader rebound. The stock's one-year total shareholder return sits near 29%, highlighting upside for investors who look beyond short-term swings. The latest analysis argues the shares remain undervalued, with a fair value estimate around $4.75 and an upside case built on AI-driven automation (cirrusAI Notes and cirrusAI Voice) that could lift EBITDA margins and operating leverage. However, the bull case faces real risks, including intensified competition from larger tech rivals and uncertain adoption in new healthcare segments. For readers who want to test scenarios, the piece suggests building your own CareCloud narrative and screening ideas. In sum, near-term strength contrasts with longer-term valuation questions.
  • Aramark (ARMK) Valuation Reassessed After Recent Share Movement
    November 8, 2025, 4:00 PM EST. Aramark (ARMK) has pulled back slightly after a multi-year run, yet shares book solid long-term returns: 5-year TSR +62%, 3-year +40%, and a positive year-to-date. Our latest analysis sets a fair value of $45.10 versus a last close of $37.80, signaling potential upside if growth catalysts materialize. Key drivers include accelerating multi-year contracts in Sports & Entertainment, Education, and Healthcare as organizations outsource non-core work. The stock trades at a PE ratio ~27.5x, a premium to the hospitality average and the firm's own fair multiple, reflecting growth expectations. Risks center on labor cost pressures and possible shifts to automation that could dent margins. Investors can explore the full narrative and a self-built view to judge whether current prices price in future growth.
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)
Previous Story

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Breaking: Eos Energy & MN8 Secure Huge 750 MWh U.S. Battery Storage Deal – Are Stocks Set to Skyrocket?
Next Story

Eos Energy (EOSE) News Today: Price Target Uplift, Fresh Downgrade, and 70% Warrant Surge — What’s Moving the Stock (Nov 8, 2025)

Go toTop